Avastin.net

Avastin in combination with other standard anticancer agents and treatment modalities

Avastin significantly increased efficacy in combination with immunotherapy in the AVOREN RCC study¹⁰

Reprinted from The Lancet, 370, Escudier B, et al., 2103–11, Copyright 2007, with permission from Elsevier

• The ability to apply direct and continuous VEGF inhibition with Avastin in combination with other treatment modalities may increase the available therapeutic options in a number of tumour types.

• In addition to chemotherapy, other types of systemic therapy used in the treatment of cancer include
  • immunotherapy
  • endocrine therapy
  • targeted agents (those acting via recognition of a specific tumour cell marker, e.g. trastuzumab for HER–2).

• Immunotherapy is commonly used in the treatment of RCC
  • in a phase III trial, Avastin significantly increased PFS (p<0.0001) and ORR (p<0.0001) in combination with IFN-α compared with IFN-α plus placebo (figure).¹⁰

• Endocrine therapies, such as aromatase inhibitors, and the targeted agent trastuzumab are each used to treat specific subgroups of patients with mBC
  • ongoing phase III studies are investigating Avastin in combination with these treatment modalities.